These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 19942479

  • 1. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [Abstract] [Full Text] [Related]

  • 2. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [Abstract] [Full Text] [Related]

  • 3. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, Lopez-Yurda M, Swijnenburg RJ, Punt CJA, Dutch Colorectal Cancer Study Group.
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [Abstract] [Full Text] [Related]

  • 4. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 5. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators.
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [Abstract] [Full Text] [Related]

  • 6. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J.
    J Clin Oncol; 2013 Jun 01; 31(16):1931-8. PubMed ID: 23569301
    [Abstract] [Full Text] [Related]

  • 7. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
    Ann Oncol; 2014 May 01; 25(5):1018-25. PubMed ID: 24585720
    [Abstract] [Full Text] [Related]

  • 8. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A.
    Ann Oncol; 2013 Aug 01; 24(8):2062-7. PubMed ID: 23666916
    [Abstract] [Full Text] [Related]

  • 9. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.
    World J Gastroenterol; 2010 Jul 07; 16(25):3133-43. PubMed ID: 20593498
    [Abstract] [Full Text] [Related]

  • 10. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators.
    Lancet; 2011 Jun 18; 377(9783):2103-14. PubMed ID: 21641636
    [Abstract] [Full Text] [Related]

  • 11. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH.
    PLoS Med; 2024 May 18; 21(5):e1004389. PubMed ID: 38728364
    [Abstract] [Full Text] [Related]

  • 12. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.
    Lancet Oncol; 2013 Jul 18; 14(8):749-59. PubMed ID: 23725851
    [Abstract] [Full Text] [Related]

  • 13. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.
    Lancet Oncol; 2014 May 18; 15(6):601-11. PubMed ID: 24717919
    [Abstract] [Full Text] [Related]

  • 14. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.
    Eur J Surg Oncol; 2015 Jul 18; 41(7):868-74. PubMed ID: 25865557
    [Abstract] [Full Text] [Related]

  • 15. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S.
    Lancet Oncol; 2014 Sep 18; 15(10):1065-75. PubMed ID: 25088940
    [Abstract] [Full Text] [Related]

  • 16. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC, Zakari A, Peyton JD, Boccia R, Moskowitz M, Gian V, Lipman A, Waterhouse D, LoCicero R, Earwood C, Lane CM, Meluch A.
    Oncologist; 2016 Mar 18; 21(3):279-80. PubMed ID: 26911408
    [Abstract] [Full Text] [Related]

  • 17. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.
    Ann Oncol; 2012 Jul 18; 23(7):1693-9. PubMed ID: 22219013
    [Abstract] [Full Text] [Related]

  • 18. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
    Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.
    Br J Cancer; 2012 Dec 04; 107(12):1932-7. PubMed ID: 23169296
    [Abstract] [Full Text] [Related]

  • 19. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.
    World J Gastroenterol; 2014 Apr 21; 20(15):4208-19. PubMed ID: 24764659
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.
    Ann Oncol; 2015 Apr 21; 26(4):702-708. PubMed ID: 25538173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.